Precision BioSciences: FDA Grants Orphan Drug Designation For PBGENE-DMD

(RTTNews) - Precision BioSciences (DTIL) announced the FDA has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy. PBGENE-DMD was recently granted FDA Rare Pediatric Disease designation for the treatment of DMD.

Cindy Atwell, Chief Development and Business Officer at Precision BioSciences, said: "Looking ahead, we remain in active dialogue with the FDA as we advance PBGENE-DMD toward regulatory milestones, with clinical data anticipated in 2026."

Shares of Precision BioSciences are up 6% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.